Oncolytics Biotech Valuation
| ONC Stock | CAD 1.33 0.02 1.53% |
Today, the company appears to be overvalued. Oncolytics Biotech holds a recent Real Value of C$1.21 per share. The prevailing price of the company is C$1.33. Our model determines the value of Oncolytics Biotech from analyzing the company fundamentals such as Shares Outstanding of 77.07 M, return on equity of -1.38, and Shares Owned By Institutions of 1.76 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oncolytics Biotech's valuation include:
Price Book 11.3182 | Enterprise Value 84 M | Enterprise Value Ebitda (2.45) |
Overvalued
Today
Please note that Oncolytics Biotech's price fluctuation is extremely dangerous at this time. Calculation of the real value of Oncolytics Biotech is based on 3 months time horizon. Increasing Oncolytics Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oncolytics Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oncolytics Stock. However, Oncolytics Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.33 | Real 1.21 | Hype 1.34 |
The intrinsic value of Oncolytics Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oncolytics Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oncolytics Biotech helps investors to forecast how Oncolytics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncolytics Biotech more accurately as focusing exclusively on Oncolytics Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oncolytics Biotech's intrinsic value based on its ongoing forecasts of Oncolytics Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oncolytics Biotech's closest peers.
Oncolytics Biotech Cash |
|
Oncolytics Valuation Trend
Knowing Oncolytics Biotech's actual value is paramount for traders when making sound investment determinations. Using both Oncolytics Biotech's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Oncolytics Biotech Total Value Analysis
Oncolytics Biotech is now forecasted to have takeover price of 83.97 M with market capitalization of 100.97 M, debt of 423 K, and cash on hands of 11.67 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Oncolytics Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
83.97 M | 100.97 M | 423 K | 11.67 M |
Oncolytics Biotech Asset Utilization
One of the ways to look at asset utilization of Oncolytics is to check how much profit was generated for every dollar of assets it reports. Oncolytics Biotech holds a negative application of assets of -0.71 pct., losing C$0.007133 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oncolytics Biotech shows how discouraging it operates for each dollar spent on its assets.Oncolytics Biotech Ownership Allocation
Oncolytics Biotech owns a total of 77.07 Million outstanding shares. Oncolytics Biotech holds 3.81 pct. of its outstanding shares held by insiders and 1.76 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Oncolytics Biotech Profitability Analysis
Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0.About Oncolytics Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Oncolytics Biotech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Oncolytics Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Oncolytics Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Oncolytics Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oncolytics Biotech. We calculate exposure to Oncolytics Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oncolytics Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -403 K | -423.1 K | |
| Pretax Profit Margin | (6.74) | (7.08) | |
| Operating Profit Margin | (6.81) | (7.15) | |
| Net Loss | (6.75) | (7.08) |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..